SCHEMBL24703572

SCHEMBL24703572

CC(C)N(CC1CCCN(c2ccnc3ccc(F)cc23)C1)S(C)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM4 P08173 1/20 0.42
▸ CYP8B1 Q9UNU6 1/20 0.41
▸ PIK3CA P42336 4/20 0.39
▸ CYP2D6 P10635 1/20 0.38
▸ IDO1 P14902 3/20 0.36
▸ PER2 O15055 2/20 0.36
▸ CRY1 Q16526 2/20 0.36
▸ CRY2 Q49AN0 2/20 0.36
▸ TRPA1 O75762 3/20 0.36
▸ PREP P48147 1/20 0.35
▸ EIF2AK4 Q9P2K8 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ F2RL1 P55085 1/20 0.35
▸ SLC22A12 Q96S37 1/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ PIK3CB P42338 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ PIK3CG P48736 1/20 0.34
▸ PRKDC P78527 1/20 0.34
▸ PIK3C3 Q8NEB9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25551807 0.89 CYP8B1 (0.41) CHRM4CYP8B1PIK3CACYP2D6IDO1
SCHEMBL24064750 0.88 HTT (0.47) CHRM4PIK3CACYP2D6PER2CRY1
SCHEMBL26552084 0.80 CHRM4 (0.40) CHRM4CYP8B1PIK3CACYP2D6IDO1
SCHEMBL21664350 0.77 HTT (0.44) CHRM4TRPA1MAPTPRKDC
SCHEMBL30562915 0.77 HTT (0.44) CHRM4TRPA1MAPTPRKDC
SCHEMBL21664278 0.76 LMNA (0.46) PRKDC
SCHEMBL30562930 0.76 LMNA (0.46) PRKDC
SCHEMBL21664279 0.70 GBA1 (0.42) EIF2AK4MAPT
SCHEMBL21664258 0.69 HTT (0.50) CHRM4PIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL30562899 0.69 HTT (0.50) CHRM4PIK3CAPIK3CDPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230172932-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RESEARCH INSTITUTE (US) 2023-06-08 — — US disclosed
US-20230172932-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RESEARCH INSTITUTE (US) 2023-06-08 — — US disclosed
US-11524010-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors SOUTHERN RESEARCH INSTITUTE (US) 2022-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524010-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors TXN, TXNL1, TXN2 CHRM4 4647/4885CYP8B1 2828/4885PIK3CA 2895/4885
US-20230172932-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS TXN, TXNL1, TXN2 CHRM4 4647/4885CYP8B1 2828/4885PIK3CA 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback